People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Pharmaceuticals, Biotechnology, Other, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Emmaus Life Sciences, Inc. | — | Pharmaceuticals | Series B | $102.9M | $2.9M | 2014 |
| Matinas BioPharma Holdings, Inc. | — | Biotechnology | Series B | $39.5M | $9.0M | 2025 |
| ORIG3N, Inc. | — | Other | Series B | $32.8M | $434.9M | 2018 |
| Biologics Inc | — | Other Health Care | Pre-Seed | $822K | $25.3M | 2010 |
Robin Smith at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robin Smith on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Jones | 1 | 19 |
| Clay Thorp | 1 | 10 |
| John Pappajohn | 1 | 10 |
| Byron Smith | 1 | 8 |
| Natasha Giordano | 1 | 5 |
| Elona Baum | 1 | 5 |
| Geoffrey Harris | 1 | 4 |
| Daniel Hoffman | 1 | 4 |
| David B. Jones | 1 | 3 |
| Roelof Rongen | 1 | 3 |
| Amir F. Heshmatpour | 1 | 3 |
| Richard Turner | 1 | 3 |
| Robert Dickey | 1 | 3 |
| Evelyn D'An | 1 | 3 |
| Richard W. Turner | 1 | 2 |
| Andrew H. Sassine | 1 | 2 |
| Robin Y. Smith | 1 | 2 |
| Andrew Sassine | 1 | 2 |
| Richard Myers | 1 | 2 |
| Walter Schindler | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.